0001209191-16-111281.txt : 20160331
0001209191-16-111281.hdr.sgml : 20160331
20160331184056
ACCESSION NUMBER: 0001209191-16-111281
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160329
FILED AS OF DATE: 20160331
DATE AS OF CHANGE: 20160331
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC
CENTRAL INDEX KEY: 0001175505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260038620
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-365-5600
MAIL ADDRESS:
STREET 1: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sarena Francis Willard
CENTRAL INDEX KEY: 0001423786
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36070
FILM NUMBER: 161544492
MAIL ADDRESS:
STREET 1: C/O FIVE PRIME THERAPEUTICS, INC.
STREET 2: 2 CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-03-29
0
0001175505
FIVE PRIME THERAPEUTICS INC
FPRX
0001423786
Sarena Francis Willard
TWO CORPORATE DRIVE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
EVP, Gen Counsel and Secretary
Common Stock
2016-03-29
4
M
0
4450
8.49
A
88284
D
Common Stock
2016-03-29
4
S
0
4450
40.00
D
83834
D
Common Stock
2016-03-30
4
M
0
5550
8.49
A
89384
D
Common Stock
2016-03-30
4
S
0
5550
40.01
D
83834
D
Employee Stock Option (right to buy)
8.49
2016-03-29
4
M
0
926
0.00
D
2021-07-13
Common Stock
926
0
D
Employee Stock Option (right to buy)
8.49
2016-03-29
4
M
0
3524
0.00
D
2022-01-01
Common Stock
3524
10297
D
Employee Stock Option (right to buy)
8.49
2016-03-30
4
M
0
5550
0.00
D
2022-01-01
Common Stock
5550
4747
D
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on October 27, 2015.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.025, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
This option is fully vested and immediately exercisable.
/s/ Francis Sarena, Attorney-in-fact
2016-03-31